Kinaxo Enters into an Agreement with Boehringer Ingelheim
Building on its existing quantitative Cellular Target ProfilingTM capabilities, Kinaxo will now employ high end mass spectrometry-based technologies to quantitatively analyze post-translational modifications of proteins. This new service will make it possible to determine the effects of compounds on proteome-wide signal transduction pathways, providing a detailed and comprehensive picture of their in vivo mode of action in cultured cells or animal tissue. Such analyses will also facilitate identifying new biomarkers and drug targets.
In the initial phase of this collaboration Kinaxo will undertake two studies on behalf of Boehringer Ingelheim. The first will be a cell line analysis project to measure the effects of an enzyme inhibitor on the acetylation status of the cellular proteome. In the second study, Kinaxo will use its new phosphoproteomics platform to determine differences in the signal transduction pathway activation status of a specific neuronal tissue when comparing wild type with a genetically modified mouse strain modelling a defined disease state. The aim of this study is to identify new drug targets.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!